Investment ThemesDetailed Quotes
Weight Loss Drugs
Watchlist
GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
- 1987.496
- +29.760+1.52%
Close Jul 12 16:00 ET
1994.533High1957.749Low
1957.749Open1957.735Pre Close41.24MVolume6Rise72.32P/E (Static)4.33BTurnover--Flatline0.39%Turnover Ratio1.89TMarket Cap1Fall1.70TFloat Cap
Constituent Stocks: 7Top Rising: ALT+2.86%
Sign in to post a comment
im bored. It's late. I might as well update my last post and see how i did.
Well, that went swell 😁 that's my post from the 10th. It received 23k views with 1 cry face and 1 sell comment (2 broke readers💔).
You can read it if you haven't. Here is how I did.
early in the day
And here is how we closed
$iShares Russell 2000 ETF(IWM.US$ $iShares Russell 2000 ETF(IWM.US$
Pow Pow 💥
$Trump Media & Technology(DJT.US$
$GameStop(GME.US$
this is going to go, it's called buil...
Well, that went swell 😁 that's my post from the 10th. It received 23k views with 1 cry face and 1 sell comment (2 broke readers💔).
You can read it if you haven't. Here is how I did.
early in the day
And here is how we closed
$iShares Russell 2000 ETF(IWM.US$ $iShares Russell 2000 ETF(IWM.US$
Pow Pow 💥
$Trump Media & Technology(DJT.US$
$GameStop(GME.US$
this is going to go, it's called buil...
+5
19
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Big potiental for Russell 2000, REITs & Bond markets in second half year of 2024.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
loading...
13
3
$Viking Therapeutics(VKTX.US$ told you guys this goes green, weak hands just got cheated by market makers.
Morning Movers
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
39
6
$Viking Therapeutics (VKTX.US)$ competition is good, Pfizer joining the game means that vktx is on right path, means other larger players will look at vktx for acquisition in order to compete with pfizer
4
$Pfizer(PFE.US$Pfizer Moves Forward With Once-Daily Weight Loss Pill
No comment yet
I Am 102927471 :